Search

Sparsentan

[L45300] On April 24, 2024, sparsentan was granted conditional marketing authorization by the European Commission for the treatment of adults with primary IgAN.[L51559] … [A257330,L45300] Sparsentan is first in its class and orally active, and was created by merging the structural elements of [irbesartan], an AT₁R antagonist, and biphenylsulfonamide, an ET<sub

Myristic acid

Aminocaproic acid

An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.

Iopamidol

Iopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.

Gefitinib

It is marketed by AstraZeneca under the trade name Iressa.

Cintredekin besudotox

Cintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual

Sucralfate

It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076]. … It is considered a _cytoprotective agent_, protecting cells in the gastrointestinal tract from damage caused by agents such as gastric acid, bile salts, alcohol, and acetylsalicylic acid (aspirin), among

Lactitol

[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.[L11803]

Garetosmab

[L63940] By preventing this aberrant signaling, it reduces the formation of new abnormal bone.[L63940] It is administered by intravenous infusion every four weeks. … [L63940] Garetosmab-grts was approved by the FDA on August 19, 2026 to reduce the number of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP.

Chlorquinaldol

Chlorquinaldol is currently approved by the European Medicines Agency as a combination tablet with promestriene for the treatment of bacterial vaginosis.[F4552]